Legend Biotech Corp. (LEGN)
34.86
+1.38
(+4.11%)
USD |
NASDAQ |
Jun 10, 16:00
34.86
0.00 (0.00%)
After-Hours: 16:26
Legend Biotech Enterprise Value : 5.775B for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 5.775B |
| June 08, 2026 | 5.409B |
| June 05, 2026 | 5.614B |
| June 04, 2026 | 5.907B |
| June 03, 2026 | 6.238B |
| June 02, 2026 | 6.293B |
| June 01, 2026 | 4.293B |
| May 29, 2026 | 4.599B |
| May 28, 2026 | 4.804B |
| May 27, 2026 | 4.815B |
| May 26, 2026 | 5.005B |
| May 22, 2026 | 4.976B |
| May 21, 2026 | 4.721B |
| May 20, 2026 | 4.745B |
| May 19, 2026 | 4.527B |
| May 18, 2026 | 4.534B |
| May 15, 2026 | 4.640B |
| May 14, 2026 | 4.833B |
| May 13, 2026 | 4.846B |
| May 12, 2026 | 4.771B |
| May 11, 2026 | 4.276B |
| May 08, 2026 | 4.745B |
| May 07, 2026 | 4.828B |
| May 06, 2026 | 4.900B |
| May 05, 2026 | 4.817B |
| Date | Value |
|---|---|
| May 04, 2026 | 4.446B |
| May 01, 2026 | 3.909B |
| April 30, 2026 | 3.896B |
| April 29, 2026 | 3.757B |
| April 28, 2026 | 3.903B |
| April 27, 2026 | 3.920B |
| April 24, 2026 | 3.966B |
| April 23, 2026 | 3.983B |
| April 22, 2026 | 4.341B |
| April 21, 2026 | 4.210B |
| April 20, 2026 | 4.182B |
| April 17, 2026 | 3.462B |
| April 16, 2026 | 3.445B |
| April 15, 2026 | 3.342B |
| April 14, 2026 | 3.004B |
| April 13, 2026 | 2.820B |
| April 10, 2026 | 2.906B |
| April 09, 2026 | 2.914B |
| April 08, 2026 | 2.932B |
| April 07, 2026 | 2.875B |
| April 06, 2026 | 3.002B |
| April 02, 2026 | 3.087B |
| April 01, 2026 | 3.071B |
| March 31, 2026 | 2.894B |
| March 30, 2026 | 2.660B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Protagonist Therapeutics, Inc. | 6.262B |
| AbbVie, Inc. | 461.77B |
| Capricor Therapeutics, Inc. | 1.242B |
| Viking Therapeutics, Inc. | 2.785B |
| Arcutis Biotherapeutics, Inc. | 2.740B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -54.46M |
| Revenue (Quarterly) | 306.01M |
| Total Expenses (Quarterly) | 360.47M |
| EPS Diluted (Quarterly) | -0.2942 |
| Gross Profit Margin (Quarterly) | 37.23% |
| Profit Margin (Quarterly) | -17.80% |
| Earnings Yield | -3.90% |
| Normalized Earnings Yield | -3.870 |